ORsa and 95% CI of colorectal cancer and colorectal cancer subtypes per 1 unit increase in ln plasma CRP concentrationsb.
| CRC subgroup | n complete cases/controlsc | OR (95% CI) | Pheterogeneityd |
|---|---|---|---|
| All CRC | 835/817 | 1.03 (0.97–1.09) | |
| Sex | |||
| Male | 437/428 | 1.03 (0.95–1.12) | 0.824 |
| Female | 398/389 | 1.02 (0.94–1.11) | |
| BRAF/KRAS mutation status | |||
| BRAF mutated | 123/116 | 1.11 (0.96–1.27) | 0.354 |
| KRAS mutated | 137/138 | 1.05 (0.91–1.20) | |
| BRAF/KRAS wild-type | 320/314 | 0.99 (0.91–1.08) | |
| MSI status | |||
| MSI | 78/70 | 1.05 (0.87–1.27) | 0.833 |
| MSS | 504/498 | 1.03 (0.96–1.09) | |
| Tumor location | |||
| Right colon | 258/245 | 1.02 (0.91–1.13) | 0.426 |
| Left colon | 247/248 | 1.09 (0.98–1.22) | |
| Rectum | 324/318 | 0.99 (0.90–1.09) | |
| Disease stage | |||
| Stage I–II | 395/385 | 1.01 (0.93–1.10) | 0.641 |
| Stage III–IV | 390/383 | 1.04 (0.96–1.14) | |
| Lag time | |||
| <5 years | 134/134 | 1.13 (0.96–1.32) | 0.583 |
| 5–10 years | 202/198 | 0.98 (0.85–1.12) | |
| 10–15 years | 251/245 | 1.01 (0.90–1.13) | |
| >15 years | 248/240 | 1.03 (0.93–1.14) | |
| Disease stage/lag time | |||
| Stage III–IV/lag time <5 years | 64/61 | 1.32 (1.01–1.73) | 0.288 |
| Stage III–IV/lag time 5–10 years | 90/88 | 0.96 (0.77–1.19) | |
| Stage III–IV/lag time 10–15 years | 124/122 | 1.01 (0.87–1.18) | |
| Stage III–IV/lag time >15 years | 112/112 | 1.02 (0.88–1.18) | |
| BMIe, kg/m2 | |||
| <25 | 317/354 | 0.99 (0.97–1.02) | 0.129 |
| 25–30 | 384/343 | 1.03 (1.00–1.06) | |
| >30 | 134/120 | 1.02 (0.98–1.06) | |
Abbreviation: CRC, colorectal cancer.
↵aMultivariable ORs adjusted for age, sex, cohort, sample year and fasting status, smoking status, recreational physical activity, alcohol intake, diabetes mellitus, and BMI (model 3). For estimates from model 1 and 2, see Supplementary Table S1.
↵bFrom multiple imputation data.
↵cNumbers (n) per subgroup represent complete cases and controls with complete covariate data, molecular data for the remaining cases were imputed. Complete estimates for all adjusted models for imputed and complete case data are presented in Supplementary Table S1 for comparison.
↵dPheterogeneity between subtypes was tested with Wald test comparing the observed overall log OR and subtype-specific log ORs from the final multivariable model (model 3).
↵eORs from unconditional logistic regression model (model 2) adjusted for all covariates listed above, except BMI.